ALS Mutations Stiffen Profilin, Steer Protein Toward Aggregation

Several different mutations in the tiny profilin-1 are responsible for some familial forms of amyotrophic lateral sclerosis. According to computational models published in the August 30 Scientific Reports, these variants restrict the protein’s flexibility, straining its relationship with actin and potentially many other partners. The mutations also make the protein more hydrophobic, coaxing it to aggregate. The authors, led by Mahmoud Kiaei at the University of Arkansas for Medical Sciences in Little Rock, propose that the structural constraints lead to a toxic mix of misfolding, aggregation, and loss of function that eventually fell motor neurons during aging.

Actin Up. Scientists propose that mutation-induced structural constraints in profilin lead to ALS by causing a toxic mix of misfolding, aggregation, and loss of function due to weakening its association to actin. [Courtesy of Kiaei et al., 2018, Scientific Reports.]

Mutations in profilin-1 (PFN1) account for 1 to 2 percent of familial ALS cases (see Jul 2012 news; Jun 2015 news). At just 140 amino acids in length, the protein contains only two interaction domains. With one, it binds actin monomers and plays an essential role in their polymerization and in the formation of the cytoskeleton. With the other, PFN1 latches onto proteins that contain poly-L-proline (PLP) motifs. These proteins carry out a variety of functions. Profilin binds upward of 50 partners, suggesting its influence stretches well beyond the cytoskeleton. Cell culture and mouse models indicate that ALS-causing mutations in the PFN1 gene destabilize the protein, promote its aggregation, and even instigate the aggregation of TDP-43, another player in ALS pathogenesis (see Oct 2016 news; Tanaka et al., 2016; Fil et al., 2017). However, researchers have yet to nail down which of these mechanisms ultimately steers motor neurons toward their demise (see April 2017 news).

Kiaei and colleagues investigated how two different mutations changed the protein’s shape. Using a previously published crystal structure of PFN1 in complex with actin and PLP, they simulated the structural and functional consequences of the glycine-118-valine (G118V) and threonine-109-methionine (T109M) mutations (Ferron et al., 2007). According to the crystal structure, G118 interacts directly with actin via a hydrogen bond, and the simulations indicated that switching this residue to valine, a larger nonpolar amino acid, would restrict PFN1’s flexibility and weaken its association with actin. Furthermore, the conformational changes caused by the valine substitution led to greater exposure of an adjacent valine residue—V119. Together, these exposed sticky residues boosted PFN1’s overall hydrophobicity, a property known to increase the likelihood of aggregation.

Small Socialite.
PFN1 (light blue) interacts with PLP (top, blue strand) and actin (green). The G118 and T109 residues mutated in ALS interact with actin and PLP, respectively. [Courtesy of Kiaei et al., 2018, Scientific Reports.]

The T109 residue resides adjacent to, but is not part of, the PLP binding site. However, the computational simulations revealed that substituting the threonine with the bulkier methionine would shift the conformation of residues that do contact PLP, leading to weaker binding. Similar to the scenario with G118V, the T109M mutation also made PFN1 more rigid and hydrophobic. The findings suggest that a combination of rigidity and hydrophobicity would weaken the protein’s associations with its binding partners, and promote its aggregation.

How might these structural shifts lead to motor neuron demise that occurs only with aging? Kiaei explained that in the G118V mouse model he developed, aggregates of PFN1 start accumulating in motor neurons prior to the onset of motor symptoms. He proposed that early in life, neurons manage to recognize and dispose of the misfolded protein translated from the mutant copy of PFN1. During this time, the cells make do with their single good copy of the gene. However, at some point in the aging process, motor neurons fail to clear the accumulating misfolded protein, which then aggregates and ensnares other proteins, perhaps including the normal copy of PFN1. The mutant protein may also wreak havoc by virtue of weakened associations with its binding partners, he added, but he thinks toxic gain of function primarily drives ALS in these familial cases.

Kiaei noted that as part of the protein’s normal life cycle, PFN1 is tagged for disposal via ubiquitin. He speculated that the increased rigidity of the protein caused by the mutations may limit its efficient labeling and disposal.

In his lab and through a company he founded called Rock Gen Therapeutics, Kiaei is testing whether small molecules that stabilize PFN1 can prevent the toxic cascade. He is using a similar strategy to stabilize proteins that aggregate in other neurodegenerative diseases as well.

Featured Paper

Kiaei M, Balasubramaniam M, Govind Kumar V, Shmookler Reis RJ, Moradi M, Varughese KI. ALS-causing mutations in profilin-1 alter its conformational dynamics: A computational approach to explain propensity for aggregation. Sci Rep. 2018 Aug 30;8(1):13102. PubMed.


Fil D, DeLoach A, Yadav S, Alkam D, MacNicol M, Singh A, Compadre CM, Goellner JJ, O’Brien CA, Fahmi T, Basnakian AG, Calingasan NY, Klessner JL, Beal FM, Peters OM, Metterville J, Brown RH Jr, Ling KK, Rigo F, Ozdinler PH, Kiaei M. Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. Hum Mol Genet. 2017 Feb 15;26(4):686-701. PubMed.

Tanaka Y, Nonaka T, Suzuki G, Kametani F, Hasegawa M. Gain-of-function profilin 1 mutations linked to familial amyotrophic lateral sclerosis cause seed-dependent intracellular TDP-43 aggregation. Hum Mol Genet. 2016 Apr 1;25(7):1420-33. Epub 2016 Jan 28 PubMed.

Ferron F, Rebowski G, Lee SH, Dominguez R. Structural basis for the recruitment of profilin-actin complexes during filament elongation by Ena/VASP. EMBO J. 2007 Oct 31;26(21):4597-606. Epub 2007 Oct 4 PubMed.

Further Reading

Profilin may act up at neuromuscular junctions in ALS

Wu CH, Giampetruzzi A, Tran H, Fallini C, Gao FB, Landers JE. A Drosophila model of ALS reveals a partial loss of function of causative human PFN1 mutants. Hum Mol Genet. 2017 Jun 1;26(11):2146-2155. PubMed.

Henty-Ridilla JL, Juanes MA, Goode BL. Profilin Directly Promotes Microtubule Growth through Residues Mutated in Amyotrophic Lateral Sclerosis. Curr Biol. 2017 Nov 20;27(22):3535-3543.e4. PubMed.

Wu CH, Fallini C, Ticozzi N, Keagle PJ, Sapp PC, Piotrowska K, Lowe P, Koppers M, McKenna-Yasek D, Baron DM, Kost JE, Gonzalez-Perez P, Fox AD, Adams J, Taroni F, Tiloca C, Leclerc AL, Chafe SC, Mangroo D, Moore MJ, Zitzewitz JA, Xu ZS, van den Berg LH, Glass JD, Siciliano G, Cirulli ET, Goldstein DB, Salachas F, Meininger V, Rossoll W, Ratti A, Gellera C, Bosco DA, Bassell GJ, Silani V, Drory VE, Brown RH Jr, Landers JE. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012 Aug 23;488(7412):499-503. PubMed.

To view commentaries, primary articles and linked stories, go to the original posting on here.

Copyright © 1996–2018 Biomedical Research Forum, LLC. All Rights Reserved.

actin axonal transport cytoskeleton disease-als profilin topic-genetics topic-preclinical
Share this: